Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression

Pharmacogenomics Journal

Volumn 13, Issue 5, 2013, Pages 396-402

  Nguyen, T D ^a   Markova, S ^a   Liu, W ^a   Gow, J M ^a   Baldwin, R M ^a   Habashian, M ^a   Relling, M V ^c   Ratain, M J ^b   Kroetz, D L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

ABC transporter; ABCC2; allelic imbalance; MRP2; pharmacogenetics; promoter

Indexed keywords

ADENINE; CYTOSINE; DNA; GUANINE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; THYMINE;

5' UNTRANSLATED REGION; ABCC2 GENE; AFRICAN AMERICAN; ALLELE; ALLELIC IMBALANCE; ARTICLE; ASIAN AMERICAN; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; GENE EXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER PARENCHYMA; PACIFIC ISLANDER; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSLATION INITIATION;

ALLELES; CELL LINE, TUMOR; HAPLOTYPES; HEP G2 CELLS; HUMANS; LIVER; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84884591802     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.20     Document Type: Article

References (39)

1. Paulusma CC, Oude Elferink RP. The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J Mol Med 1997; 75: 420-428.
2. Buchler M, Konig J, Brom M, Kartenbeck J, Spring H, Horie T et al. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 1996; 271: 15091-15098.
3. Dietrich CG, Ottenhoff R, de Waart DR, Oude Elferink RP. Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology 2001; 167: 73-81.
4. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J et al. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 2000; 83: 375-383.
5. Nies AT, Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 2007; 453: 643-659.
6. Jemnitz K, Heredi-Szabo K, Janossy J, Ioja E, Vereczkey L, Krajcsi P. ABCC2/Abcc2: a multispecific transporter with dominant excretory functions. Drug Metab Rev 2010; 42: 402-436.
7. Toh S, Wada M, Uchiumi T, Inokuchi A, Makino Y, Horie Y et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 1999; 64: 739-746.
8. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 2006; 42: 441-449.
9. Haenisch S, May K, Wegner D, Caliebe A, Cascorbi I, Siegmund W. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics 2008; 18: 357-365.
10. Haenisch S, Zimmermann U, Dazert E, Wruck CJ, Dazert P, Siegmund W et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 2007; 7: 56-65.
11. Hirouchi M, Suzuki H, Itoda M, Ozawa S, Sawada J, Ieiri I et al. Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ ABCC2. Pharm Res 2004; 21: 742-748.
12. Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK et al. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 2006; 44: 62-74.
13. Ranganathan P, Culverhouse R, Marsh S, Mody A, Scott-Horton TJ, Brasington R et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008; 35: 572-579.
14. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006; 194: 1481-1491.
15. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112: 3754-3762.
16. Stockel B, Konig J, Nies AT, Cui Y, Brom M, Keppler D. Characterization of the 50-flanking region of the human multidrug resistance protein 2 (MRP2) gene and its regulation in comparison with the multidrug resistance protein 3 (MRP3) gene. Eur J Biochem 2000; 267: 1347-1358.
17. Tanaka T, Uchiumi T, Hinoshita E, Inokuchi A, Toh S, Wada M et al. The human multidrug resistance protein 2 gene: functional characterization of the 50-flanking region and expression in hepatic cells. Hepatology 1999; 30: 1507-1512.
18. Qadri I, Hu LJ, Iwahashi M, Al-Zuabi S, Quattrochi LC, Simon FR. Interaction of hepatocyte nuclear factors in transcriptional regulation of tissue specific hormonal expression of human multidrug resistance-associated protein 2 (abcc2). Toxicol Appl Pharmacol 2009; 234: 281-292.
19. Naesens M, Kuypers DR, Verbeke K, Vanrenterghem Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 2006; 82: 1074-1084.
20. Choi JH, Ahn BM, Yi J, Lee JH, Nam SW, Chon CY et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 2007; 17: 403-415.
21. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007; 132: 272-281.
22. Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K et al. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/ leucovorin (FOLFIRI). Biol Pharm Bull 2008; 31: 2137-2142.
23. Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 2002; 25: 1356-1359.
24. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007; 110: 138-147.
25. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007; 63: 1161-1169.
26. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 2006; 7: 1211-1221.
27. Kroetz DL. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol 2006; 24: 4225-4227.
28. Zamboni WC, Ramanathan RK, McLeod HL, Mani S, Potter DM, Strychor S et al. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes. Invest New Drugs 2006; 24: 393-401.
29. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27: 2604-2614.
30. Hoblinger A, Grunhage F, Sauerbruch T, Lammert F. Association of the c.3972C4T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer. Digestion 2009; 80: 36-39.
31. Han B, Gao G, Wu W, Gao Z, Zhao X, Li L et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer 2011; 72: 238-243.
32. Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la Cruz M et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci USA 2003; 100: 5896-5901.
33. Latif S, Bauer-Sardina I, Ranade K, Livak KJ, Kwok PY. Fluorescence polarization in homogeneous nucleic acid analysis II: 50-nuclease assay. Genome Res 2001; 11: 436-440.
34. de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007; 81: 42-49.
35. Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J 2011; 11: 25-34.
36. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Hasler R et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2-24C4T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics 2009; 19: 353-362.
37. Nishioka C, Sakaeda T, Nakamura T, Moriya Y, Okamura N, Tamura T et al. MDR1, MRP1 and MRP2 genotypes and in vitro chemosensitivity in Japanese patients with colorectal adenocarcinomas. Kobe J Med Sci 2004; 50: 181-188.
38. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C et al. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos 2005; 33: 896-904.
39. Hilger E, Reinthaler EM, Stogmann E, Hotzy C, Pataraia E, Baumgartner C et al. Lack of association between ABCC2 gene variants and treatment response in epilepsy. Pharmacogenomics 2012; 13: 185-190.